Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy

J Oncol Pract. 2018 Mar;14(3):198-199. doi: 10.1200/JOP.2017.027326. Epub 2017 Dec 19.

Authors

Masood Sadaat¹, Sekwon Jang¹

Affiliation

¹ Inova Schar Cancer Institute, Fairfax, VA.

PMID: 29257718
DOI: 10.1200/JOP.2017.027326

No abstract available

Publication types

Case Reports

MeSH terms

Allografts
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Graft Survival / drug effects*
Graft Survival / immunology
Humans
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation* / adverse effects
Kidney Transplantation* / methods
Male
Middle Aged
Prednisone / pharmacology
Prednisone / therapeutic use
Sirolimus / pharmacology
Sirolimus / therapeutic use
Skin Neoplasms / diagnosis
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Immunosuppressive Agents
pembrolizumab
Prednisone
Sirolimus